title: Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer.
abstract: BACKGROUND
  Cabazitaxel and AA have been approved by the US Food and Drug Administration for use after docetaxel in mCRPC. Recently, CAB appeared to be active when given after AA. AA is capable of inducing AR splice variants that confer ligand-independent AR transactivation. Because microtubule-targeting agents impair AR nuclear transport and activity, we raised concerns about CAB efficacy after AA failure in mCRPC.
  
  
  METHODS
  One hundred thirty mCRPC patients received AA after docetaxel treatment in compassionate programs. Of them, 24 (18.4%) subsequently received CAB. We retrospectively reviewed their data using conventional methods.
  
  
  RESULTS
  Twenty-four patients received a median of 4 (range, 1-13) CAB cycles. Nineteen (79.1%) of them received primary prophylaxis with growth factors. Median patient characteristics were: age 65 (range, 57-85) years; Gleason score: 8 (range, 6-10); and PSA: 128.1 (range, 0.01-1700) ng/mL. A PSA response (≥ 50% decrease from baseline) occurred in 6 (31.5%) of 19 evaluable patients (95% confidence interval [CI], 11.8-54.2%). CAB therapy obtained a partial response in 2 of the 13 (15.3%) evaluable patients (95% CI, 2.9-45.4%). Median survival from initiation of CAB was 8.2 (95% CI, 3.34-13.05) months, from AA 16.1 (95% CI, 11.56-20.64) and from docetaxel 32.0 (95% CI, 11.56-39.69).
  
  
  CONCLUSIONS
  A limited number of patients with mCRPC received CAB after docetaxel and AA treatment. In this selected population, CAB was active.
authors: Department of Oncology, Assaf Harofeh Medical Center, Zerifin, Israel, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Israel. Electronic address: a_sella@asaf.health.gov.il.
authors: Avishay
authors: A
authors: Sella
authors: Department of Oncology, Sheba Medical Center, Ramat Gan, Israel.
authors: Tal
authors: T
authors: Sella
authors: Department of Oncology, Rambam Health Care Campus, Haifa, Israel.
authors: Avivit
authors: A
authors: Peer
authors: Department of Oncology, Sheba Medical Center, Ramat Gan, Israel.
authors: Raanan
authors: R
authors: Berger
authors: Department of Oncology, Hadassah Medical Center, Jerusalem, Israel.
authors: Stephen Jay
authors: SJ
authors: Frank
authors: Department of Oncology, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel.
authors: Eli
authors: E
authors: Gez
authors: Department of Oncology, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel.
authors: David
authors: D
authors: Sharide
authors: Department of Oncology, Wolfson Medical Center, Holon, Israel.
authors: Henry
authors: H
authors: Hayat
authors: Department of Oncology, Assaf Harofeh Medical Center, Zerifin, Israel, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Israel.
authors: Ekaterina
authors: E
authors: Hanovich
authors: Department of Oncology, Assaf Harofeh Medical Center, Zerifin, Israel, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Israel.
authors: Svetlana
authors: S
authors: Kovel
authors: Department of Oncology, Rabin Medical Center, Petach-Tikva, Israel.
authors: Eli
authors: E
authors: Rosenbaum
authors: Department of Oncology, Rabin Medical Center, Petach-Tikva, Israel.
authors: Victoria
authors: V
authors: Neiman
authors: Department of Oncology, Meir Medical Center, Kfar-Saba, Israel.
authors: Daniel
authors: D
authors: Keizman
mesh_terms: D000069501:Abiraterone Acetate; D000368:Aged; D000369:Aged, 80 and over; D000736:Androstenes / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage*
chemical_list: D000736:Androstenes; D043823:Taxoids; D000077143:Docetaxel; C552428:cabazitaxel; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate
keywords: Androgen receptor; Chemotherapy; Docetaxel and Abiraterone failure; Metastatic castration-resistant prostate cancer; Sequential therapy